ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$13.00 USD
-0.06 (-0.46%)
Updated Aug 14, 2024 03:59 PM ET
Pre-Market: $13.02 +0.02 (0.15%) 9:24 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SPRY 13.00 -0.06(-0.46%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
Other News for SPRY
Raymond James ups ARS to strong buy, cites FDA neffy approval
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Raymond James upgrades ARS Pharmaceuticals to Strong Buy on tailwinds
Starbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz